Skip to main content
Clinical Trials/TCTR20220318004
TCTR20220318004
Enrolling By Invitation
Phase 2

Efficacy of triamcinolone acetonide dissolving microneedle patch for the treatment of hypertrophic scar and keloid: A randomized, double-blinded, placebo-controlled split-scar study

Division of Dermatology, Department of internal medicine, Faculty of medicine, Thammasat University0 sites10 target enrollmentMarch 18, 2022

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Triamcinolone acetonide dissolving microneedle patch for hypertrophic scar or keloid
Sponsor
Division of Dermatology, Department of internal medicine, Faculty of medicine, Thammasat University
Enrollment
10
Status
Enrolling By Invitation
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 18, 2022
End Date
March 30, 2022
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Division of Dermatology, Department of internal medicine, Faculty of medicine, Thammasat University

Eligibility Criteria

Inclusion Criteria

  • 1\. Healthy male or female participants, aged 18\-60\.
  • 2\. Participants had hypertrophic scar or keloid more than 2 cm without any previous treatments, more than 6 months of intralesional steroids, or more than 3 months of light \& laser treament.
  • 3\. Participants who are willing to join the project after receiving a detailed description of the project and signing a consent form for the study.
  • 4\. Participants can follow the testing method to follow up on treatment results throughout the study period and can report side effects that arise from the study immediately

Exclusion Criteria

  • 1\. Participants who had history of treatment with intralesional steroids less than 6 months or light \& laser treatment less than 3 months.
  • 2\. Participants who had a history of using systemic corticosteroids (oral, intramuscular, intravenous), chemotherapy, warfarin, heparin, or systemic retinoids
  • 3\. Participants who had active dermatitis or skin infection at the study site
  • 4\. Participants who are pregnant, breastfeeding or planning to become pregnant.
  • 5\. Participants who had a history of liver diseases, renal diseases.
  • 6\. Participants with any type of diabetes mellitus.

Outcomes

Primary Outcomes

Not specified

Similar Trials